Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milk allergy immunotherapy - DBV Technologies

Drug Profile

Milk allergy immunotherapy - DBV Technologies

Alternative Names: Cows milk allergy immunotherapy; Viaskin Milk

Latest Information Update: 19 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DBV Technologies
  • Developer DBV Technologies; The Childrens Hospital of Philadelphia
  • Class Anti-inflammatories; Food allergy immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Eosinophilic oesophagitis; Milk hypersensitivity

Most Recent Events

  • 20 Nov 2018 DBV Technologies completes a phase II trial in Eosinophilic oesophagitis (In children, In adolescents) in USA (Topical) (NCT02579876)
  • 26 Feb 2018 Preliminary efficacy and adverse events data from a phase I/II MILES trial in Milk hypersensitivity released by DBV Technologies
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Milk-hypersensitivity(In children) in France (Topical, Patch)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top